Market Cap
$33.6B
RPRX
Royalty Pharma plc
$57.43 ▼ -0.35%
Prev close $57.63Market cap$33.6B
ConsensusStrong Buy
12-mo target$65.13 (+13.4%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders) Biotech & Drug Discovery
Snapshot
The big-picture read on RPRX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (88%)
Insider Activity
$0.00 buy / $40.9M sell
Insider Net $
-$40.9M
SEC Reports
13
Press Releases
5
Price chart 30d -9.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 23, 2027 fda_pdufa
PDUFA: RPRX — deucrictibant in hereditary angioedema attacks — 2027-04-23
FDA target action date 2027-04-23 for RPRX (Royalty Pharma plc). Drug: deucrictibant. Indication: he
Sep 30, 2026 Insider
Bassler Bonnie L was granted 642 shares
Director @ $58.41 ($37.5K)
Sep 28, 2026 Insider
Urist Marshall sold 4,126 shares
EVP, Research & Investments @ $57.88 ($238.8K)
Sep 22, 2026 Insider
Sep 4, 2026 Press Hite Christopher sold 3,927 shares
EVP & Chairman, Partnering @ $58.93 ($231.4K)
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in athe
Impact 5/10
Two senior executives at Royalty Pharma (EVP/Chairman Hite and EVP/CFO Coyne) sold a combined $6.54M in open-market sale
CLUSTER — Impact 3/10
Errol B. De Souza, a former affiliate of Royalty Pharma, filed two Form 144 notices on August 12, 2026, signaling intent
144 — Impact 3/10
Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cash Flow per diluted s
8-K — Impact 6/10
Analyst ratings buy % +2.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 7, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jul 13, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| May 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| May 7, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Apr 21, 2026 | UBS | MAINTAIN | Buy | 55% |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Aug 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Jul 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Jun 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 5 | 9 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 8 covering analysts think RPRX trades over the next 12 months.
$65.13 +13.4% upside Buy
Current$57.43 Low$61.00 Median$65.50 High$70.00 8 analysts
$61.00$70.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 11 neutral · avg impact 3.2/10.Plus 5 press releases.
NEUTRALCLUSTER3/10
Two senior executives at Royalty Pharma (EVP/Chairman Hite and EVP/CFO Coyne) sold a combined $6.54M
Aug 20, 2026
NEUTRAL1443/10
Errol B. De Souza, a former affiliate of Royalty Pharma, filed two Form 144 notices on August 12, 20
Aug 12, 2026
BULLISH8-K6/10
Royalty Pharma reported Q2 2026 results with Portfolio Receipts of $773M (+6% YoY) and Portfolio Cas
Aug 5, 2026
NEUTRALCLUSTER2/10
Two EVP-level insiders at Royalty Pharma (RPRX) sold a combined $7.85M in shares over a 7-day window
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Apr 23, 2027
fda_pdufa
PDUFA: RPRX — deucrictibant in hereditary angioedema attacks — 2027-04-23
FDA target action date 2027-04-23 for RPRX (Royalty Pharma plc). Drug: deucrictibant. Indication: hereditary angioedema attacks. FDA accepted NDA for
Nov 27, 2026
fda_pdufa
PDUFA: RPRX — neladalkib in non-small cell lung cancer — 2026-11-27
FDA target action date 2026-11-27 for RPRX (Royalty Pharma plc). Drug: neladalkib. Indication: non-small cell lung cancer. FDA accepted NDA for nelada
Sep 22, 2026
short_volume
Short Volume: RPRX — 56.9% short (0.5M / 0.8M)
Short: 461,616 | Exempt: 13,103 | TRF Vol: 811,680 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Sep 7, 2026
dark_pool
Dark Pool: RPRX — 6.3M shares, 83,661 trades
Week starting 2026-09-07. Total ATS volume: 6,250,585 shares across 83,661 trades.
Sep 4, 2026
fda
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.18 | $1.14–$1.22 | 0.6% | +1.6% | 4↑ 1↓ | $0.9B | 6 |
| Next Q | $1.55 | $1.52–$1.63 | 5.6% | +1.8% | 4↑ 1↓ | $0.9B | 5 |
| Current FY | $5.34 | $5.28–$5.44 | 10.6% | +0.6% | 6↑ 0↓ | $3.5B | 6 |
| Next FY | $5.73 | $5.01–$6.23 | 7.3% | +0.9% | 5↑ 0↓ | $3.8B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.181 | — |
| 7d ago | $1.171 | +0.010 |
| 30d ago | $1.161 | +0.019 |
| 60d ago | $1.138 | +0.042 |
| 90d ago | $1.130 | +0.050 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$40.9M — $0.00 bought, $40.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Bassler Bonnie L | Director | AWARD | 642 | $58.41 | $37.5K |
| Sep 28, 2026 | Urist Marshall | EVP, Research & Investments | SELL | 4,126 | $57.88 | $238.8K |
| Sep 22, 2026 | Hite Christopher | EVP & Chairman, Partnering | SELL | 3,927 | $58.93 | $231.4K |
| Sep 22, 2026 | Hite Christopher | EVP & Chairman, Partnering | SELL | 96,073 | $58.51 | $5.6M |
| Aug 19, 2026 | Hite Christopher | EVP & Chairman, Partnering | GIFT | 16,800 | — | — |
| Aug 18, 2026 | Hite Christopher | EVP & Chairman, Partnering | SELL | 100,000 | $59.97 | $6.0M |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 9,230 | $58.59 | $540.8K |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | SELL | 1,772 | $59.14 | $104.8K |
| Aug 7, 2026 | Urist Marshall | EVP, Research & Investments | GIFT | 3,000 | — | — |
| Aug 7, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | GIFT | 30,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RPRX.
Shares short
11,647,565
Settlement Sep 15, 2026
Change vs prior
-2.1%
Semi-monthly cycle
Days to cover
3.3
At avg daily volume
Of shares outstanding
≈2.0%
Estimate — not % of float
All RPRX filing & press-release reports (18)
- PRESS-RELEASE reportSep 4, 2026
- CLUSTER reportAug 20, 2026
- 144 reportAug 12, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportJul 3, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportMay 28, 2026
- 8-K reportMay 28, 2026
- CLUSTER reportMay 22, 2026
- CLUSTER reportMay 15, 2026
- 144 reportMay 14, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 15, 2026
- DEFA14A reportApr 10, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026